Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
daplusiran
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
Daplusiran is an investigational small interfering RNA (siRNA) therapeutic developed for the treatment of chronic hepatitis B and hepatitis D infections. It is a GalNAc-conjugated siRNA that targets the hepatitis B virus (HBV) X and S open reading frames (ORFs), leading to RNA interference-mediated suppression of viral gene expression. The drug has demonstrated significant reductions in hepatitis B surface antigen (HBsAg) levels in clinical trials, with effects persisting for years after dosing. Daplusiran is being evaluated both as monotherapy and in combination with tomligisiran or other agents, aiming to achieve functional cure rates superior to current standard therapies. The drug was initially developed by Arrowhead Pharmaceuticals and has since been further developed by Johnson & Johnson/Janssen and GSK[1][4][5][6][7].
- Other names
- daplusiran/tomligisiranDAP/TOM
02
Targets
HBV (Hepatitis B virus)HBV X RNA (Hepatitis B virus X region RNA transcript)
Beyond the preview
Go deeper on daplusiran.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on daplusiran.